加载中
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
最新数据
HK$4.015
+HK$0.105 · +2.69%
盘中时间采用HKT。市场数据可能有所延迟。
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
日内区间
当前HK$4.015
52周区间
当前HK$4.015
盘中时间采用HKT。市场数据可能有所延迟。
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
日内区间
当前HK$4.015
52周区间
当前HK$4.015
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（CNY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 9.11亿 CNY | 3.68亿 CNY | 2.25亿 CNY | 1557.2万 CNY | — |
| 销货成本 | 1.79亿 CNY | 7482.4万 CNY | 2827.7万 CNY | 200.5万 CNY | 1.15亿 CNY |
| 毛利 | 7.32亿 CNY | 2.93亿 CNY | 1.97亿 CNY | 1356.7万 CNY | −1.15亿 CNY |
| 研究与开发 | 3.36亿 CNY | 4.38亿 CNY | 4.58亿 CNY | 5.24亿 CNY | 7.91亿 CNY |
| 销售、一般及管理费用 | 3.54亿 CNY | 2.38亿 CNY | 1.3亿 CNY | 1.41亿 CNY | 1.56亿 CNY |
| 营业费用 | 6.45亿 CNY | 6.84亿 CNY | 1.92亿 CNY | 7.18亿 CNY | 10.1亿 CNY |
| 利息收入 | 1200.89万 CNY | 466.7万 CNY | 670.9万 CNY | 817.3万 CNY | 414.3万 CNY |
| 利息支出 | 2855.05万 CNY | 2165万 CNY | 1467.7万 CNY | 746.7万 CNY | 269.6万 CNY |
| 折旧和摊销 | 9130.03万 CNY | 8391.2万 CNY | 1.03亿 CNY | 9544.6万 CNY | 7718.3万 CNY |
| 营业利润 | 8743.01万 CNY | −3.91亿 CNY | 479.6万 CNY | −7.04亿 CNY | −10.1亿 CNY |
| 净利润 | 2.55亿 CNY | −4.11亿 CNY | −2209.6万 CNY | −6.89亿 CNY | −10.11亿 CNY |
公司数据更新于 2026年10月6日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
iShares Core MSCI Emerging Markets ETFIEMG629.32万0.00%1621.9亿 USD0.09%US$83.355-0.27%
State Street SPDR Portfolio Emerging Markets ETFSPEM97.47万0.01%174.64亿 USD0.07%US$52.875+0.10%
WisdomTree China ex-State-Owned Enterprises FundCXSE32.06万0.07%4.49亿 USD0.32%US$34.94-0.45%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX30.69万0.05%6.64亿 USD0.65%US$72.11+0.38%
Avantis Emerging Markets Equity ETFAVEM26.19万—291.66亿 USD0.33%US$96.425-0.24%
iShares Core MSCI Total International Stock ETFIXUS24.02万0.00%590.95亿 USD0.07%US$96.37+0.28%
Global X - Aging Population ETFAGNG18.61万0.21%8743.85万 USD0.50%US$36.224+0.34%
iShares MSCI China Small-Cap ETFECNS17.94万0.29%6174.66万 USD0.59%US$27.29-0.09%iShares Core MSCI Emerging Markets ETFIEMGState Street SPDR Portfolio Emerging Markets ETFSPEMWisdomTree China ex-State-Owned Enterprises FundCXSEState Street SPDR S&P Emerging Markets Small Cap ETFEWXAvantis Emerging Markets Equity ETFAVEMiShares Core MSCI Total International Stock ETFIXUSGlobal X - Aging Population ETFAGNGiShares MSCI China Small-Cap ETFECNSAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
